224 research outputs found
Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant
Octreotide
A peptide inhibiting the release of growth hormone was originally detected accidentally during studies of the distribution of growth hormone–releasing factor in the hypothalamus of rats. This peptide, called somatostatin, proved to be a cyclic peptide consisting of 14 amino acids. Subsequent work has considerably expanded this initially simple concept of somatostatin as a peptide whose main function is the regulation of growth hormone secretion. Today, somatostatin is best regarded as a phylogenetically ancient, multigene family of peptides with two important bioactive products: somatostatin-14 and somatostatin-28, the latter a congener of somatostatin-14 extended at the N-terminal
Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours
Five somatostatin receptor (sst) subtype genes, sst(1), sst(2), sst(3),
sst(4) and sst(5), have been cloned and characterised. The five sst
subtypes all bind natural somatostatin-14 and somatostatin-28 with high
affinity. Endocrine pancreatic and endocrine digestive tract tumours also
express multiple sst subtypes, but sst(2) predominance is generally found.
However, there is considerable variation in sst subtype expression between
the different tumour types and among tumours of the same type. The
predominant expression of sst(2) receptors on pancreatic endocrine or
carcinoid tumours is essential for the control of hormonal hypersecretion
by the octapeptide somatostatin analogues such as octreotide and
lanreotide. Somatostatin and its octapeptide analogues are also able to
inhibit proliferation of normal and tumour cells. The high density of
sst(2) or sst(5) on pancreatic endocrine or carcinoid tumours further
allows the use of radiolabelled somatostatin analogues for in vivo
visualisation. The predominant expression of sst(2) receptors in these
tumours and the efficiency of sst(2) receptors to undergo agonist-induced
internalisation is also essential for the application of radiolabelled
octapeptide somatostatin analogues. Currently,
[(111)In-DTPA(0)]octreotide, [(90)Y-DOTA(0),Tyr(3)]octreotide,
[(177)Lu-DOTA(0)Tyr(3)]octreotate, [(111)In-DOTA(0)]lanreotide and
[(90)Y-DOTA(0)]lanreotide can be used for this purpose
Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency
Cardiovascular risk is increased in GH deficiency (GHD). GHD adults are
frequently abdominally obese and display features of the metabolic
syndrome. Otherwise healthy abdominally obese subjects have low GH levels
and show features of the metabolic syndrome as well. We investigated in
healthy nonobese males the effect of the GH receptor antagonist
pegvisomant in different metabolic conditions. This is a model for acute
GHD without the alterations in body composition associated with GHD. We
compared the effect of pegvisomant with that of placebo before and after 3
d of fasting. In addition, we investigated the effect of pegvisomant under
normal, i.e. fed, conditions. Three days of fasting as well as pegvisomant
alone decreased serum free IGF-I levels (1.0 +/- 0.15 vs. 0.31 +/- 0.05
ng/ml and 0.86 +/- 0.23 vs. 0.46 +/- 0.23 ng/ml, respectively). Fasting in
combination with pegvisomant also decreased serum free IGF-I levels (1.0
+/- 0.15 vs. 0.31 +/- 0.07 ng/ml). Treatment with pegvisomant had no
additional influence on the decline of free IGF-I induced by fasting.
Pegvisomant alone had no influence on insulin sensitivity. The increase in
insulin sensitivity induced by fasting was comparable to the increase in
insulin sensitivity induced by fasting combined with pegvisomant. Among
serum lipid concentrations, only serum triglycerides increased
significantly as a result of pegvisomant alone (1.0 +/- 0.2 vs. 1.6 +/-
0.4 mmol/liter). The changes in lipid concentrations induced by fasting
alone or pegvisomant were not different from those induced by pegvisomant
alone. von Willebrand factor antigen levels declined significantly under
the influence of pegvisomant alone (1.1 +/- 0.07 vs. 0.8 +/- 0.06 U/ml).
In conclusion, in different metabolic conditions the GH receptor
antagonist pegvisomant induces no significant acute changes in the major
risk markers for cardiovascular disease. These data suggest that the
secondary metabolic changes, e.g. abdominal obesity or inflammatory
factors, that develop as a result of long-standing GHD are of primary
importance in the pathogenesis of atherosclerosis in patients with GHD
Comparison of [18F]DOPA and [68Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy
BACKGROUND: In treatment of neuroendocrine neoplasms (NENs), confirmation of somatostatin receptor expression with 68Ga-DOTA somatostatin analogues is mandatory to determine eligibility for peptide receptor radionuclide therapy (PRRT). [18F]DOPA can detect additional lesions compared to [68Ga]DOTA-TOC. The aim of this study was to explore differences in tumour detection of both tracers and their relevance for selecting patients for PRRT. We retrospectively studied eight patients with NENs who underwent both [68Ga]DOTA-TOC and carbidopa-enhanced [18F]DOPA PET/CT, before first-time PRRT with [177Lu]DOTA-TATE. Tracer order was influenced due to stock availability or to detect suspected metastases with a second tracer. On CT, disease control was defined as a lesion showing complete response, partial response, or stable disease, according to RECIST 1.1. CRITERIA: RESULTS: Seven patients with in total 89 lesions completed four infusions of 7.4 GBq [177Lu]DOTA-TATE, one patient received only two cycles. Before treatment, [18F]DOPA PET/CT detected significantly more lesions than [68Ga]DOTA-TOC PET/CT (79 vs. 62, p < .001). After treatment, no difference in number of lesions with disease control was found for [18F]DOPA-only (5/27) and [68Ga]DOTA-TOC-only lesions (4/10, p = .25). [18F]DOPA detected more liver metastases (24/27) compared to [68Ga]DOTA-TOC (7/10, p = .006). Six patients showed inpatient heterogeneity in treatment response between [18F]DOPA-only and [68Ga]DOTA-TOC-only lesions. CONCLUSIONS: Response to PRRT with [177Lu]DOTA-TATE was comparable for both [68Ga]DOTA-TOC- and [18F]DOPA-only NEN lesions. [18F]DOPA may be capable of predicting response to PRRT while finding more lesions compared to [68Ga]DOTA-TOC, although these additional lesions are often small of size and undetected by diagnostic CT
- …